Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 85%
filed 2026-08-03
Item 5.02
The section discloses the appointment of David Kutil as Chief Financial Officer on July 28, 2026, along with material terms of his employment agreement including base salary of $275,000 and bonus eligibility. While the section also mentions termination of Sefton Cohen as Chief Revenue Officer, the primary focus and detail is on Kutil's appointment to a named executive officer role, making exec_appointment the most salient event. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
EX-99.1
The press release announces the appointment of Cassie McLean as a member of the Management Board and Chief Executive Officer of the Care Delivery operating segment, effective August 1, 2026. This is a material executive appointment to a senior leadership role at a major global healthcare company. The disclosure also notes that Craig Cordola, the previous CEO of Care Delivery, has departed from that role, but the principal disclosed action is McLean's appointment to the Management Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
Matthew Whitlock was appointed as Chief Investment Officer of Chiron Real Estate Inc. and Inter-American Management LLC effective August 3, 2026. The disclosure details his appointment, employment agreement with $400,000 base salary, equity inducement awards valued at $350,000, and severance provisions. While the section also describes Alfonzo Leon's transition from CIO to Strategic Advisor, the principal disclosed action centers on Whitlock's appointment to a senior executive role with substantial compensation and equity arrangements, making this an executive appointment event.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-03
EX-99.1
The press release announces the appointment of Michael J. Loparco as an independent non-executive director effective August 3, 2026. While the exhibit also discloses a proposed U.S. redomiciliation, the principal disclosed action is the director appointment. Loparco's extensive executive background (CEO of Symbotic and Jabil, current CEO of OrcaWorcs.ai, board member of Sanmina) and relevance to IperionX's manufacturing scale-up make this material to investors assessing board composition and governance capability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-03
Item 5.02
John B. Eagan was appointed as General Counsel and Corporate Secretary effective August 1, 2026, succeeding Wm. Gordon Prescott who retired July 31, 2026. Eagan will oversee all legal affairs and serve on the Executive Management Committee.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-08-03
EX-99.1
The press release announces the appointment of two new directors to POET's Board of Directors effective August 1, 2026: Dr. Bardia Pezeshki and Jean F. Rankin. Both appointments are described with detailed biographical information highlighting their relevant expertise in technology, optical communications, governance, and corporate transactions. While the exhibit also discloses Jean-Louis Malinge's resignation, the principal disclosed action is the two director appointments, which would materially affect investor assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-08-03
Item 5.02
Jeffrey Naylor was appointed as an independent Class I director and Audit Committee Chair of Petco Health & Wellness Company, Inc., effective August 1, 2026, filling a vacancy created by Cameron Breitner's resignation. Naylor brings extensive retail and financial leadership experience, including prior service as CFO of TJX Companies and current board memberships at Synchrony Financial and Wayfair.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-03
Item 5.02
The section discloses both the appointment of Paul Sacks as Interim Chief Financial Officer (effective August 4, 2026) and the departure of Matthew Prusak from the same role. While both events are disclosed, the appointment of a CFO—a named executive officer—is the principal action requiring disclosure and is material to investors assessing the company's leadership continuity. The departure is secondary context explaining why the appointment was necessary.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-03
Item 5.02
The filing discloses the appointment of Nicole Rapport as Vice President and Chief Accounting Officer effective August 16, 2026, with detailed background, compensation terms ($285,000 base salary plus $125,000 minimum bonus), and eligibility for equity participation. While the filing also mentions Eugene Shnayderman's concurrent departure, the principal disclosed action centers on Rapport's appointment to a named executive officer role with specified compensation arrangements, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
The disclosure centers on the appointment of Matthew Casaccia to the Board of Managers of Invesco Capital Management LLC (the Sponsor) effective August 3, 2026, with concurrent appointment to the Audit Committee. Although the filing also mentions the concurrent resignation of Jordan Krugman, the principal action disclosed is Casaccia's appointment to a governance role. The appointment of a board member and audit committee member at the sponsor of an ETF is material to investors in the fund.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
The disclosure centers on the appointment of Matthew Casaccia to the Board of Managers of Invesco Capital Management LLC (the Sponsor) effective August 3, 2026, with concurrent appointment to the Audit Committee. Although the filing also mentions the concurrent resignation of Jordan Krugman, the principal action disclosed is Casaccia's appointment to a governance role. This is a material governance event affecting the fund's sponsor's board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Julie Sawyer Montgomery was appointed as President and Chief Executive Officer of Danaher, effective October 1, 2026, and was also appointed to the Board and three Board committees, representing a major leadership succession at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
The filing discloses the appointment of James Ahlers as Chief Financial Officer effective July 30, 2026. While the disclosure includes compensatory details (base salary of $450,000, target bonus of 45%, and equity grants of 51,000 stock options and 25,500 RSUs), the principal action is the appointment of a named executive officer to a key financial leadership role. The appointment of a CFO is material to investors as it affects the company's financial reporting and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
The filing discloses the appointment of Myriam J. Curet, M.D. as a new Class II director to Mobia's Board, effective July 30, 2026, increasing the Board size from seven to eight members. Dr. Curet brings substantial medical and board experience from senior roles at Intuitive Surgical and current directorships at Inspire Medical Systems and Stereotaxis, Inc. This is a material governance event affecting board composition and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-08-03
Item 5.02
Matthew Bromberg was appointed to the Board of Directors effective July 29, 2026, following the IPO, with compensatory arrangements including a director retainer and RSU award.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
EX-99.1
The company appointed Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer, both reporting directly to the CEO. These material C-suite appointments strengthen the company's leadership structure for global expansion and commercialization of its drug pipeline as multiple Phase III registrational studies advance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 75%
filed 2026-08-03
The 6-K discloses the appointment of Nancy Yang as an independent director, chairman of the compensation committee, and member of the audit and nominating committees effective August 1, 2026. While the filing also mentions the concurrent resignation of Heung Ping Wong, the primary substantive action disclosed is Ms. Yang's appointment to the Board with specific committee assignments and qualifications as an audit committee financial expert. This is material as it affects Board composition and governance structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
The 6-K discloses the appointment of Ms. Qian Yi Amanda Chew as Chief Product Officer (CPO) by the Board of Directors, effective August 17, 2026. This is a named executive appointment to a C-suite officer position, representing a material change in leadership that would affect a reasonable investor's assessment of the company's management structure and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
William Sherman was appointed to the Board of Directors effective July 31, 2026, and simultaneously appointed as interim chair of the Audit Committee and chair of the Compensation Committee.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-03
EX-99.1
The press release announces the appointment of Mr. Martin Ngai Lam Cheung as an independent director of Pinnacle Food Group Limited, effective August 1, 2026. The disclosure details his extensive qualifications, including prior board and audit committee experience at multiple public companies, CFO tenure at China Zenix Auto International Limited, and professional certifications. The Board has determined he meets independence requirements under Nasdaq Listing Rule 5605(a)(2) and qualifies as an "audit committee financial expert." This is a clear executive/director appointment that would be material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-03
Item 5.02
Five new directors (Matt Herrington, Karly Dyck, Kunal Dusad, Brett Fox, and Aleks Novakovic) were appointed effective July 31, 2026, with Matt Herrington appointed as Chief Executive Officer and Karly Dyck as Chief Financial Officer, in connection with the consummation of the transaction and resulting in a material restructuring of the board and executive leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Peter Graham was appointed as a director of Invesco Mortgage Capital Inc., effective August 3, 2026, with concurrent appointments to the Audit, Compensation, and Nomination and Corporate Governance committees. Graham brings over 30 years of financial services experience, including prior CFO roles at Sallie Mae, PRA Group, and General Electric.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Jonathan M. Dale was appointed as President of Avidbank Holdings, Inc. and Avidbank effective August 3, 2026, reporting to Chairman and CEO Mark D. Mordell. The appointment is part of the Board's deliberate succession-planning strategy to provide leadership continuity, organizational depth, and stability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
Mark V. Anquillare was appointed as a director of Teladoc Health, effective August 3, 2026, and concurrently appointed to the audit and compensation committees. The Board determined he qualifies as an independent director and audit committee financial expert.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
The filing discloses the appointment of Michael J. Grissinger as a director of Lipocine Inc., effective August 3, 2026. Item 5.02 explicitly states the Board expanded to five members and appointed Mr. Grissinger as a director, with details on his compensation (2,000 share option grant and $55,000 annual retainer). The press release emphasizes his extensive pharmaceutical and M&A experience from Johnson & Johnson, positioning him as a valuable addition to advance the company's pipeline and partnerships. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-03
The filing discloses both the departure of Bradford Amman as CFO and the appointment of Roman Franklin as CFO, effective July 31, 2026. While both events occur, the principal disclosed action centers on the appointment of Franklin as the new CFO with a detailed background and compensatory arrangements under a Master Services Agreement with CFO Portal. The departure is presented as context for the transition. The appointment of a new CFO with material compensation terms (annual retainer of $324,000 plus equity awards) is material to investors assessing leadership and financial management continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
The filing discloses the appointment of Amiee Bayer-Thomas to CAVA's Board of Directors effective July 29, 2026, along with her appointment to the Audit Committee and Nominating, Governance and Sustainability Committee. This is a clear director appointment under Item 5.02, representing a material governance change that would affect a reasonable investor's assessment of the company's leadership and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-03
Item 5.02
People Inc appointed Neil Vogel as Chief Executive Officer and Timothy Quinn as Chief Financial Officer, both effective August 5, 2026, representing a significant leadership transition at the registrant.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 98%
filed 2026-08-03
EX-99.1
BioNTech's Supervisory Board appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer, succeeding Prof. Ugur Sahin. This is a material executive appointment of a C-suite officer (CEO) at a major biopharmaceutical company, disclosed via press release on August 3, 2026, with an effective date by February 1, 2027. The appointment of a new CEO is a significant governance and leadership event that would affect a reasonable investor's assessment of the company's strategic direction and execution capability.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-31
Item 5.02
The filing discloses both a director departure (N.A. Hansen's resignation from the board effective July 30, 2026) and a director appointment (S.D. Abrahams appointed to the board effective July 30, 2026). While both events occurred, the principal substantive disclosure centers on the appointment of Abrahams, who brings CFO-level experience from ExxonMobil and will serve on key committees (finance, safety and sustainability). The appointment of a new director with significant corporate experience is the more forward-looking material event for investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-31
Item 5.02
BorgWarner appointed Rajesh Kalathur as an independent director to its Board of Directors on July 30, 2026, increasing board size from eight to nine members.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-31
EX-99.1
The news release announces Christian Milau's appointment as President and Chief Executive Officer effective September 30, 2026, and his election to the Board of Directors. While the release also discloses George Burns' retirement as CEO and several other management transitions, the principal disclosed action is Milau's assumption of the CEO role and board seat. The appointment of a new CEO is material to investors' assessment of leadership continuity and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-31
Item 5.02
The filing discloses the appointment of David Wiens as Chief Executive Officer (effective August 17, 2026) and Shane Parrow as President and Chief Operating Officer (effective July 27, 2026), along with their election to the Board of Directors. While the disclosure includes compensatory arrangements (base salary, bonuses, equity awards, and severance terms), the principal disclosed action centers on these two executives taking on significant leadership roles, making exec_appointment the most salient classification. The material nature is evident from the C-suite positions and substantial equity grants ($1.65M and $650K respectively).
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-31
EX-99.1
The press release announces that an Extraordinary General Meeting approved the appointment of Andrea Cesaroni as a member of the Executive Board, effective 31 July 2026, in the role of Chief Risk Officer (CRO). This is a material executive appointment to a named executive position at a major global financial institution, affecting the composition of the top leadership team alongside the CEO and CFO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-31
Item 5.02
The filing discloses the appointment of Daniel Gish as an independent trustee of the Board effective July 30, 2026, with committee assignments to the Nominating and Governance Committee and Audit Committee. While the section also mentions Daniel Kasell's resignation on July 29, 2026, the substantive focus and detail of the disclosure centers on Gish's appointment, including his background, qualifications, and independence certifications. Board-level appointments are material governance events affecting investor assessment of the company's leadership and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-31
Item 5.02
The filing discloses conditional appointments of three key executives—Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO—effective upon stockholder approval of acquisition-related proposals at the September 25, 2026 Special Meeting. While the section also mentions conditional resignations of the current CEO and COO, the Board's affirmative action on July 29, 2026 was to approve these three appointments, making the appointment the principal disclosed action. The appointments are material as they represent a complete change in the executive leadership team contingent on stockholder approval of the Orphai acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-31
The filing discloses the appointment of Stephen P. Ribaudo as Executive Vice President and Chief Operating Officer effective September 1, 2026, along with detailed compensation arrangements including base salary of $670,000, equity grants totaling at least $1,794,000 for the first year, and a $1,000,000 make-whole RSU award. This is a material C-suite appointment that would affect investor assessment of the company's leadership and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-31
EX-99.1
The press release announces the appointment of Dean Martin as SVP, Head of the Automotive Business Unit, effective September 1, 2026, succeeding Adar Segal who is stepping down. This is a clear executive appointment of a named officer to a senior leadership role overseeing a key business unit. The disclosure emphasizes Martin's 25+ years of automotive industry experience and his role in driving the company's automotive growth strategy, making this material to investors assessing management quality and execution capability.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-31
EX-99.1
The exhibit is a news release announcing the appointment of Katherine Lee to Sun Life's Board of Directors, effective July 31, 2026. This is a clear executive/governance appointment of a director to the board. Ms. Lee's extensive background in financial services, 20+ years of board experience at major companies (BCE, Colliers, PSIB, Chorus Aviation), and her role as former President and CEO of GE Capital Canada make this a material board appointment that would affect a reasonable investor's assessment of the company's governance and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-31
Item 5.02
The filing discloses the appointment of three new directors (Carlos Septién, Michelle Cervantes Vivanco, and Ernesto Gómez Berjón) and their simultaneous appointment as Chief Operating Officer, Chief Financial Officer, and Chief Growth Officer, respectively, effective July 29, 2026. While the filing also includes governance amendments and a reverse stock split, the principal disclosed action centers on these executive and board appointments, which are material to investors assessing the registrant's leadership and control structure, particularly in the context of Trafalgar Asset Management's acquisition of control.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-31
The filing discloses the appointment of two new directors—Pua Chee Aun and Lee Seongil—to the Board on July 28, 2026, with both appointed to the Audit and Compensation Committees. While the filing also mentions the resignation of Li Wei and Michael Coyne, the substantive focus and forward-looking action is the appointment of the two new directors with specified class terms and committee roles. For a SPAC or acquisition company, board composition changes are material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-31
Item 5.02
Douglas J. Williamson, M.D. was appointed as a director to Vistagen's Board of Directors, effective July 29, 2026. Dr. Williamson brings nearly three decades of neuroscience drug development and regulatory expertise, including prior roles as Chief Medical Officer and executive positions at major pharmaceutical firms, strengthening the board's clinical and development capabilities.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-31
Item 5.02
Roberto Stanichi was promoted to President, Chief Marketing and Brand Officer on July 29, 2026, a material elevation in role and responsibility within Mattel's executive leadership. The promotion includes compensatory arrangements with a base salary of $900,000 and stock grants totaling $3.9 million, and represents a significant governance event affecting the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-31
Item 5.02
Three independent directors—Daniel M. McCabe, Becky Fallon, and Sean Michael Deegan—were appointed to the Board effective July 23, 2026, in connection with the Company's IPO, with assignments to audit and compensation committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
Alexander Benjamin Spiro was appointed as a Class III director on July 24, 2026, to fill a vacancy created by an increase in board size from 9 to 10 directors, and was also appointed to the Compensation Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-30
Item 5.02
Jason K. Bowlin was promoted to Senior Vice President – Rail effective August 1, 2026, succeeding Gregory W. Lippard. Lippard transitioned to Senior Vice President – Special Rail Projects and is scheduled to retire on December 31, 2026. The appointment of Bowlin to this key executive position reporting to the EVP & COO represents a material leadership succession.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
The Board appointed William E. Waltz as a new independent director effective October 29, 2026, and also appointed him to the Compensation Committee. This is a clear executive appointment event. While the filing also mentions the Board increased in size from nine to ten members, the principal disclosed action is the appointment of a named executive to the Board and a Board committee, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
William Hornbuckle, the CEO and President of MGM Resorts International, was appointed to Vail Resorts' Board of Directors effective August 3, 2026, with the Board size increased from nine to ten members. This is a clear executive appointment of a prominent hospitality industry leader to the company's board, which is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-30
Item 5.02
AAON appointed two independent directors, Robert L. Buttermore III and Patrick J. Jermain, to its Board of Directors effective July 28, 2026, with assignments to the Compensation and Audit Committees respectively, and amended its bylaws to increase board size from nine to eleven positions.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-30
EX-99.1
This news release announces the composition of the future Executive Leadership Team of Anglo Teck plc following the merger of Teck and Anglo American, with specific named appointments including Duncan Wanblad as CEO, Jonathan Price as Deputy CEO & Chief Strategy Officer, John Heasley as CFO, and eight other executive officers, effective upon merger completion. The announcement of a complete executive leadership structure for a major combined entity is a material governance event disclosing multiple executive appointments.
View raw filing on EDGAR →